Cyclooxygenase-2 gene expression in human breast cancer

International Journal of Oncology

Volumn 10, Issue 3, 1997, Pages 503-507

  Parkett, Michelle L ^a   Harris, Randall E ^a   Joarder, Farahnaz S ^a   Ross, Mary S ^a   Clausen, Kathryn P ^a   Robertson, Fredika M ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

breast cancer; COX 2; cyclooxygenase; nonsteroidal anti inflammatory drugs

Indexed keywords

CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL;

EID: 0030999903     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Honn KV, Bockman RS and Marnett LJ: Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 21: 833-864, 1981.
2. Schrey MP and Patel KV: Prostaglandin E2 production and metabolism in human breast cancer cells and fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72: 1412-1419, 1995.
3. Kujubu DA, Fletcher BS, Varnum BC, Lim RW and Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266: 12866-12872, 1991.
4. Xie WL, Chipman JG, Robertson DL, Eriksin RL and Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692-2696, 1991.
5. Hla T and Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89: 7384-7388, 1992.
6. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA and Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 268: 9049-9054, 1993.
7. Kujubu DA, Reddy ST, Fletcher BS and Hershman HR: Expression of the protein product of the prostaglandin synthase-2/T1510 gene in mitogen stimulated Swiss 3T3 cells. J Biol Chem 268: 5425-5430, 1993.
8. Herschman HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 13: 241-256, 1994.
9. Loll PJ and Garavito RM: The isoforms of cyclooxygenase: structure and function. Exp Opin Invest Drugs 3: 1171-1180, 1994.
10. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575-5589, 1992.
11. Rigas B, Goldman IS and Levine L: Altered cicosanoid levels in human colon cancer. J Clin Lab Med 122: 518-523, 1993.
12. Kutchera W, Jones DA, Matsunami S, Groden J, McIntyre TM, Zimmerman GA, White RL and Prescott SM: Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 93: 4816-4820, 1996.
13. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and Dubois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
14. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559, 1995.
15. Sano H, Kawahito Y, Wilder RL, Jashiramoto A, Mukai A, Asai K, Kimura S, Kato H, Kondo M and Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
16. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR and Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993.
17. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM and Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115: 952-954, 1991.
18. Suh O, Mettlin C and Petrelli NJ: Aspirin use, cancer and polyps of the large bowel. Cancer 72: 1171-1177, 1993.
19. Greenberg ER, Baron JA, Freeman DH, Mandel JS and Haile R: Reduced risk of large-bowel adenomas among aspirin users. The polyp prevention study group. J Natl Cancer Inst 85: 912-916, 1993.
20. Kune GA, Kune S and Watson LF: Colorectal cancer risk, chronic illness, operations, and medications: case-control results from the Melbourne colorectal cancer study. Cancer Res 48: 4399-4404, 1988.
21. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD and Shapiro SA: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 83: 355-358, 1991.
22. Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and ;. reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
23. Logan RFA, Little J, Hawtin PG and Hardcastle JD: Effects of aspirin and non-steroidal anti-inflammatory drugs on colon adenomas: a case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br J Med 307: 285-289, 1993.
24. Muscat JE, Stellman SD and Wynder EL: Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74: 1847-1854, 1994.
25. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A and Willett WC: Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246, 1994.
26. Peleg II, Maibach HT, Brown SH and Wilcox CM: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394-399, 1994.
27. Giovannuci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC and Speitzer FE: Aspirin use and the risk of colorectal cancer in women. N Engl J Med 333: 609-614, 1995.
28. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE and Remington PL: Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidem Biomarker Prev 5: 955-960, 1996.
29. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF and Zebro T: Prostaglandins and breast cancer. Lancet 2: 624-626, 1977.
30. Bennett A, Berstock DA, Raja B and Stamford IF: Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br J Pharmacol 66: 451P, 1979.
31. Rolland PH, Martin PM, Jacquemeier J, Rolland AM and Toga M: Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64: 1061-1070, 1980.
32. Vegote IB, van Dam PA, Laekeman GH, Uyttenbroeck FL and Herman AG: Prostacyclin/thromboxane ratio in human breast cancer. Tumor Biol 12: 261-266, 1991.
33. Fulton AM, Ownby HE, Frederick J and Brennan MJ: Relationship of tumor prostaglandin levels to early recurrance in women with primary breast cancer: clinical update. Invasion Metastasis 6: 83-94, 1986.
34. Watson DMA, Kelly RW, Hawkins RA and Miller WR: Prostaglandins in human mammary cancer. Br J Cancer 49: 459-464, 1984.
35. 2α in benign and malignant breast tumors. Br J Cancer 51: 827-836, 1985.
36. Karmali RA, Welts S, Thaler HT and Lefevre F: Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer 48: 689-696, 1983.
37. Aitokallio-Talberg A, Karkkainen J, Pantzar P, Wahlstrom T and Ylikorkala O: Prostacyclin and thromboxane in breast cancer: relationship between steroid receptor status and medroxyprogesterone acetate. Br J Cancer 51: 671-674, 1985.
38. Laekeman GM, Vergote IB, Keersmaeker GM, Heiremans J, Haensch CF, De Roy G, Uyttenbroeck FL and Herman AG: Prostacyclin and thromboxane in benign and malignant breast tumors. Br J Cancer 54: 431-437, 1986.
39. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, De Vito B, Weksler BB and Dannenberg AJ: Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56: 4424-4426, 1996.
40. Liu X-H and Rose DP: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56: 5125-5127, 1996.
41. Fulton AM and Levy JG: Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin. Int J Cancer 26: 669-673, 1980.
42. Lee PPH and Ip MM: Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostagland Leuk Essent Fatty Acids 45: 21-31, 1992.
43. Carter CA, Milholland RJ, Shea W and Ip MM: Effect of prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 43: 3559-3562, 1983.
44. McCormick DL and Moon RC: Inhibition of mammary carcinogenesis by flurbiprofen, a nonsteroidal anti-inflammatory agent. Br J Cancer 48: 859-861, 1983.
45. Fulton AM: In vivo effects of indomethacin on the growth of murine mammary tumor. Cancer Res 44: 2416-2420, 1984.
46. McCormick DL, Madigan MJ and Moon RC: Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 45: 1803-1808, 1985.
47. Harris RE, Namboodiri KK, Stellman SD and Wynder EL: Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 24: 119-120, 1995.
48. Harris RE, Namboodiri KK and Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7: 203-205, 1996.
49. Harris RE, Namboodiri KK and Farrar WB: Epidemiological study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 2: 591-592, 1995.
50. Fulton AM: Effects of indomethacin on the growth of cultured mammary tumors. Int J Cancer 33: 375-379, 1984.
51. Rose DP and Connolly JM: Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 50: 7139-7144, 1990.
52. Noguchi M, Rose DP, Earshi M and Miyazaki I: The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma. Oncology 52: 265-271, 1995.
53. Tripathi SC, Vosseller KA and McCormick DL: Arachidonic acid metabolism and cell proliferation in rat mammary carcinoma cells treated with indomethacin. Biochim Biophys Acta 1316: 5-7, 1996.